STEMPOINT CAPITAL LP
13F Reported Value
ⓘ$514.6M
incl. option notional
Equity Holdings
ⓘ$512.5M
Option Notional
ⓘ$2.1M
$525,000 puts / $1.6M calls
Holdings
82
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
STEMPOINT CAPITAL LP disclosed 82 positions worth $514.6M in its Form 13F-HR for Q1 2026 — $512.5M in common stock plus $2.1M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SRRK (Scholar Rock Holding Corp) at 9.9% of the equity portfolio, followed by $ABVX and $SNDX. During the quarter the fund opened 43 new positions and exited 38 — including a new stake in $ELVN and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (96.5% of disclosed assets). All figures are sourced directly from STEMPOINT CAPITAL LP’s Form 13F-HR filing with the SEC under CIK 1952142.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$50.9M1,035,496 sh - —
Quality
$34.9M313,791 sh - 30.0#2,378
Quality
$28.4M1,215,743 sh - —
Quality
$27.4M281,632 sh - —
Quality
$18.5M746,494 sh - $18.1M56,267 sh
- —
Quality
$14.9M499,469 sh - —
Quality
$14.4M533,378 sh - —
Quality
$14.2M363,438 sh - 28.0
Quality
$13.9M205,622 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Scholar Rock Holding Corp$SRRK | — | $50.9M | 1,035,496 |
 Abivax S.A.$ABVX | — | $34.9M | 313,791 |
 Syndax Pharmaceuticals Inc$SNDX | 30.0#2,378 | $28.4M | 1,215,743 |
 Revolution Medicines, Inc.$RVMD | — | $27.4M | 281,632 |
 Immunovant, Inc.$IMVT | — | $18.5M | 746,494 |
 Praxis Precision Medicines, Inc.$PRAX | — | $18.1M | 56,267 |
 MBX Biosciences, Inc.$MBX | — | $14.9M | 499,469 |
 Mineralys Therapeutics, Inc.$MLYS | — | $14.4M | 533,378 |
 Enliven Therapeutics, Inc.$ELVN | — | $14.2M | 363,438 |
 CG Oncology, Inc.$CGON | 28.0 | $13.9M | 205,622 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of STEMPOINT CAPITAL LP's 82 positions.
Showing top 10 of 82 holdings.
Sector Allocation
Healthcare
$494.8M
Technology
$10.5M
Other
$7.3M
Full Holdings — STEMPOINT CAPITAL LP (Q1 2026)
All 82 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SRRK | Scholar Rock Holding Corp | $50.9M | 9.9% | +17% | — |
| 2 | $ABVX | Abivax S.A. | $34.9M | 6.8% | -20% | — |
| 3 | $SNDX | Syndax Pharmaceuticals Inc | $28.4M | 5.5% | -9% | 30 |
| 4 | $RVMD | Revolution Medicines, Inc. | $27.4M | 5.3% | +354% | — |
| 5 | $IMVT | Immunovant, Inc. | $18.5M | 3.6% | +16% | — |
| 6 | $PRAX | Praxis Precision Medicines, Inc. | $18.1M | 3.5% | +167% | — |
| 7 | $MBX | MBX Biosciences, Inc. | $14.9M | 2.9% | +536% | — |
| 8 | $MLYS | Mineralys Therapeutics, Inc. | $14.4M | 2.8% | +84% | — |
| 9 | $ELVN | Enliven Therapeutics, Inc. | $14.2M | 2.8% | NEW | — |
| 10 | $CGON | CG Oncology, Inc. | $13.9M | 2.7% | NEW | 28 |
| 11 |  $BHVN | Biohaven Ltd. | $13.5M | 2.6% | NEW | — |
| 12 |  $ROIV | Roivant Sciences Ltd. | $10.7M | 2.1% | -60% | — |
| 13 |  $EYPT | EyePoint, Inc. | $10.5M | 2.0% | +129% | 10.3 |
| 14 |  $ARQT | Arcutis Biotherapeutics, Inc. | $9.7M | 1.9% | +84% | 41.2 |
| 15 |  $GPCR | Structure Therapeutics Inc. | $9.7M | 1.9% | -43% | — |
| 16 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $9.3M | 1.8% | +18% | — |
| 17 |  $DYN | Dyne Therapeutics, Inc. | $9.2M | 1.8% | -39% | — |
| 18 |  $EWTX | Edgewise Therapeutics, Inc. | $9.2M | 1.8% | -19% | — |
| 19 |  $CYTK | CYTOKINETICS INC | $8.5M | 1.7% | -12% | 28 |
| 20 |  $SYRE | Spyre Therapeutics, Inc. | $8.5M | 1.6% | +418% | — |
| 21 |  $DNLI | Denali Therapeutics Inc. | $8.2M | 1.6% | +2% | — |
| 22 |  $XENE | Xenon Pharmaceuticals Inc. | $8.2M | 1.6% | -60% | 12.9 |
| 23 |  $CLDX | Celldex Therapeutics, Inc. | $8.1M | 1.6% | NEW | 13.2 |
| 24 |  $PTGX | Protagonist Therapeutics, Inc | $7.6M | 1.5% | +22% | 24.8 |
| 25 |  $TYRA | Tyra Biosciences, Inc. | $7.4M | 1.4% | NEW | — |
| 26 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $7.2M | 1.4% | +8% | 26.8 |
| 27 |  $CELC | Celcuity Inc. | $6.9M | 1.3% | -49% | — |
| 28 |  $DFTX | Definium Therapeutics, Inc. | $6.2M | 1.2% | NEW | — |
| 29 |  $BIOA | BioAge Labs, Inc. | $5.9M | 1.2% | NEW | 28.6 |
| 30 |  $NAMS | NewAmsterdam Pharma Co N.V. | $5.8M | 1.1% | +147% | — |
| 31 |  $SRZN | Surrozen, Inc./DE | $5.7M | 1.1% | -68% | — |
| 32 |  $ACAD | ACADIA PHARMACEUTICALS INC | $5.4M | 1.1% | NEW | 69.8 |
| 33 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $5.1M | 1.0% | +18% | 26.6 |
| 34 |  $ALMS | ALUMIS INC. | $5.1M | 1.0% | NEW | 9.2 |
| 35 |  $NRIX | Nurix Therapeutics, Inc. | $4.9M | 0.9% | NEW | 13.2 |
| 36 |  $ZURA | Zura Bio Ltd | $4.5M | 0.9% | NEW | — |
| 37 |  $EVMN | Evommune, Inc. | $4.4M | 0.9% | +184% | — |
| 38 |  $TNGX | Tango Therapeutics, Inc. | $4.2M | 0.8% | NEW | 26.9 |
| 39 | — | SENSEI BIOTHERAPEUTICS INC | $4.2M | 0.8% | NEW | — |
| 40 |  $RLMD | RELMADA THERAPEUTICS, INC. | $4.2M | 0.8% | NEW | — |
| 41 |  $ERAS | Erasca, Inc. | $3.9M | 0.8% | NEW | — |
| 42 |  $JNJ | JOHNSON & JOHNSON | $3.8M | 0.7% | -56% | 72.8 |
| 43 |  $XFOR | X4 Pharmaceuticals, Inc | $3.5M | 0.7% | -5% | 29.3 |
| 44 |  $PCVX | Vaxcyte, Inc. | $3.4M | 0.7% | NEW | — |
| 45 |  $WHWK | Whitehawk Therapeutics, Inc. | $3.2M | 0.6% | -36% | 9.6 |
| 46 | — | HELIX ACQUISITION CORP III | $3.1M | 0.6% | NEW | — |
| 47 |  $TENX | TENAX THERAPEUTICS, INC. | $3.0M | 0.6% | NEW | — |
| 48 |  $ALKS | Alkermes plc. | $2.8M | 0.6% | NEW | — |
| 49 |  $PHVS | Pharvaris N.V. | $2.4M | 0.5% | +48% | — |
| 50 |  $IVVD | Invivyd, Inc. | $2.4M | 0.5% | +89% | 25.7 |
| 51 |  $JBIO | Jade Biosciences, Inc. | $2.2M | 0.4% | NEW | — |
| 52 |  $TWST | Twist Bioscience Corp | $2.0M | 0.4% | -92% | 33.3 |
| 53 |  $MPLT | MapLight Therapeutics, Inc. | $2.0M | 0.4% | +0% | — |
| 54 |  $AVTX | Avalo Therapeutics, Inc. | $2.0M | 0.4% | -1% | 4.6 |
| 55 |  $IONS | IONIS PHARMACEUTICALS INC | $2.0M | 0.4% | NEW | 37.1 |
| 56 |  $IMCR | Immunocore Holdings plc | $1.9M | 0.4% | NEW | — |
| 57 |  $FBRX | Forte Biosciences, Inc. | $1.5M | 0.3% | NEW | — |
| 58 |  $SION | Sionna Therapeutics, Inc. | $1.5M | 0.3% | NEW | — |
| 59 |  $SABS | SAB Biotherapeutics, Inc. | $1.4M | 0.3% | +156% | — |
| 60 |  $SLDB | Solid Biosciences Inc. | $1.4M | 0.3% | NEW | — |
| 61 |  $LPCN | Lipocine Inc. | $1.3M | 0.3% | NEW | — |
| 62 |  $QURE | uniQure N.V. | $1.3M | 0.3% | +80% | — |
| 63 |  $LBRX | LB PHARMACEUTICALS INC | $1.2M | 0.2% | NEW | — |
| 64 |  $CCCC | C4 Therapeutics, Inc. | $1.2M | 0.2% | NEW | 6.5 |
| 65 |  $EW | Edwards Lifesciences Corp | $1.2M | 0.2% | NEW | 67.6 |
| 66 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $1.1M | 0.2% | +111% | — |
| 67 |  $BDSX | BIODESIX INC | $1.0M | 0.2% | NEW | 32.3 |
| 68 | $SRRKCALL | Scholar Rock Holding Corp | $588,000 | — | -64% | — |
| 69 |  $STRO | SUTRO BIOPHARMA, INC. | $580,278 | 0.1% | NEW | 30.1 |
| 70 | $RVMDPUT | Revolution Medicines, Inc. | $525,000 | — | NEW | — |
| 71 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $415,626 | 0.1% | NEW | — |
| 72 | $TYRACALL | Tyra Biosciences, Inc. | $290,000 | — | NEW | — |
| 73 | $IMVTCALL | Immunovant, Inc. | $255,000 | — | NEW | — |
| 74 | — | SPDR SERIES TRUST | $164,250 | — | NEW | — |
| 75 | $SNDXCALL | Syndax Pharmaceuticals Inc | $90,000 | — | NEW | 30 |
| 76 |  $SPYCALL | SPDR S&P 500 ETF TRUST | $85,500 | — | NEW | — |
| 77 |  $QQQCALL | INVESCO QQQ TRUST, SERIES 1 | $74,200 | — | NEW | — |
| 78 |  $VTGN | Vistagen Therapeutics, Inc. | $58,187 | 0.0% | +0% | — |
| 79 |  $BSXCALL | BOSTON SCIENTIFIC CORP | $12,500 | — | NEW | 79.9 |
| 80 |  $TERNCALL | Terns Pharmaceuticals, Inc. | $7,500 | — | NEW | — |
| 81 |  $OLMACALL | Olema Pharmaceuticals, Inc. | $3,750 | — | NEW | — |
| 82 | $EWCALL | Edwards Lifesciences Corp | $1,000 | — | NEW | 67.6 |
New Positions (43)
$ELVN Enliven Therapeutics, Inc.$14.2M$CGON CG Oncology, Inc.$13.9M$BHVN Biohaven Ltd.$13.5M$CLDX Celldex Therapeutics, Inc.$8.1M$TYRA Tyra Biosciences, Inc.$7.4M$DFTX Definium Therapeutics, Inc.$6.2M$BIOA BioAge Labs, Inc.$5.9M$ACAD ACADIA PHARMACEUTICALS INC$5.4M$ALMS ALUMIS INC.$5.1M$NRIX Nurix Therapeutics, Inc.$4.9M$ZURA Zura Bio Ltd$4.5M$TNGX Tango Therapeutics, Inc.$4.2M$RLMD RELMADA THERAPEUTICS, INC.$4.2M$ERAS Erasca, Inc.$3.9MExited Positions (38)
$CNTA Centessa Pharmaceuticals plc
$ACLX Arcellx, Inc.$TERN Terns Pharmaceuticals, Inc.
$MDGL MADRIGAL PHARMACEUTICALS, INC.
$ADPT Adaptive Biotechnologies Corp
$PALI PALISADE BIO, INC.
$DRUG BRIGHT MINDS BIOSCIENCES INC.
$NKTR NEKTAR THERAPEUTICS
$CLPT ClearPoint Neuro, Inc.
$IMTX Immatics N.V.
$OCUL OCULAR THERAPEUTIX, INC
$RYTM RHYTHM PHARMACEUTICALS, INC.
$APGE Apogee Therapeutics, Inc.
$INCY INCYTE CORP
$IDYA IDEAYA Biosciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for STEMPOINT CAPITAL LP including:
Track STEMPOINT CAPITAL LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for STEMPOINT CAPITAL LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: STEMPOINT CAPITAL LP
13F Pro is an AI hedge fund tracker and stock research platform. For STEMPOINT CAPITAL LP (SEC CIK: 1952142), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in STEMPOINT CAPITAL LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.